Analyst Report: AMAT

1. EXECUTIVE SUMMARY

Applied Materials closed at $430.01 on 15 October, down 15.61% from $509.57 on 8 October, after management declined to give an industry spending forecast at its 13 October investor day. Investing.com reported that the company offered no wafer fab equipment (WFE) forecast, and BigGo Finance reported no overall revenue forecast, which left investors without a benchmark for the 2030 targets. The stock fell 6.69% on that session and a further 3.79% and 3.72% over the next two, with volume of 12,150,100 on 15 October, 1.84x the 50-session average. Lam Research, KLA and Teradyne fell between 11.32% and 13.92% over the same period, so the sector moved with Applied, while the S&P 500 slipped 0.27%. Reported results gave no reason for the fall. The brief points to uncertainty about when AI-related fab spending will arrive, plus a hot inflation print on 15 October. The shares trade at 23.3x forward earnings, and the next test is the fiscal Q4 report due around 12 November.

2. THE CATALYST

The main event was the investor day at SEMICON West on 13 October. Investing.com reported that Applied declined to give a WFE spending forecast. BigGo Finance added that there was no overall revenue forecast, although the company set 2030 profitability and share targets and the CEO said he was highly confident without offering specific near-term figures. Seeking Alpha listed the targets that were given: service revenue growth above 20%, about $12B of service revenue by 2030, non-GAAP gross margin near 54% and operating margin near 40%.

Seeking Alpha and Benzinga reported an intraday drop of about 7% during the presentation and a sixth straight loss. The close of -6.69% to $464.24 on volume of 10,876,600 was the largest daily fall in the window.

Yahoo Finance reported that a morning selloff in several chip stocks on 15 October followed hotter-than-expected inflation data, with fears that higher borrowing costs would curb AI infrastructure spending. The Stocktwits item linking the 14 to 15 October selling to DRAM ramp demand could not be opened, so it is headline-only.

3. COMPANY PROFILE

Applied Materials supplies materials engineering equipment, services and software to chipmakers through two segments, Semiconductor Systems and Applied Global Services. Its tools cover deposition, etch, rapid thermal processing, chemical mechanical planarization, metrology and inspection, wafer packaging and ion implantation. Main listed peers include Lam Research, KLA and Teradyne. The market capitalisation is $341.25bn.

Trefis reported fiscal Q3 2026 sales growth of 24.8% and an operating margin of 33.7%, against 30.6% a year earlier. Management guided fiscal Q4 revenue to $9.75B to $10.8B, against $9.12B in fiscal Q3. Trefis also noted that free cash flow for the twelve months to July 2026 slipped to $5.62B while net income rose to $9.27B. A roughly $5B EPIC Center in California was announced ahead of the investor day (Manufacturing Dive), and management said, per 24/7 Wall St citing an earnings call, that clean room space limits what the company can ship next year.

4. DEEP DIVE ANALYSIS

Do fundamentals justify the move? The reported numbers do not explain it. Pomegra described the 13 October sector sell-off as uncertainty over the timing of fab spending rather than a fall in results, and Investing.com framed the problem as AI demand not yet producing a predictable equipment spending schedule. My inference is that a stock priced for rapid growth lost its anchor when management withheld a market outlook. The August report followed a similar pattern, with 24/7 Wall St citing Reuters that upbeat guidance failed to satisfy investors wanting faster growth.

Peers. Lam Research fell 13.45%, KLA 11.32% and Teradyne 13.92%, while the fourth peer in the panel, Q, fell 5.58%. 24/7 Wall St and GuruFocus reported that Lam and KLA fell in sympathy on 13 October with Applied taking the largest hit that day. Applied's 15.61% decline is the largest of the group over the week, so most of the move is shared sector pressure with an added company-specific layer.

Analysts. Cantor Fitzgerald (C.J. Muse) reiterated Overweight with an $850 target during the investor day (Benzinga). Evercore ISI retained Outperform with a $700 target, according to Investing.com and Yahoo Finance, although a TipRanks listing on the CNN page reports a cut to $590. That conflict is unresolved. Earlier moves were more cautious: Morgan Stanley cut to $563 from $642 with an Equal-Weight rating (Benzinga, 28 September), and Mizuho cut to $590 from $650 (Benzinga, 25 August). UBS raised to $695 from $675 on 1 September.

Comparable episodes. Trefis counted 11 falls of more than 20% within 30 trading days since 2010. Across the ten with a full year of data, the median one-year gain was 46.5%, and the median deepest decline in the following year was 20.5%. The worst cases were a 42.3% maximum drawdown after March 2022 and 39.6% after April 2018. Trefis calls this a rough guide because the current fall does not meet the 20% threshold exactly.

Bull case. Fiscal Q4 guidance implies growth from $9.12B, margins are rising, capacity expansion is under way and the forward multiple of 23.3x sits well below the trailing 40.0x. Cantor's $850 target is nearly double the close.

Bear case. Without a WFE forecast the market has no way to test the 2030 goals. Free cash flow fell while net income rose, rates pressure on AI spending is a live concern, and Trefis's history shows deep further drawdowns are common after sharp falls.

5. TECHNICAL SNAPSHOT

The close of $430.01 sits below the 50-day average of $484.46 and just below the 200-day average of $437.63, and 41.8% beneath the 52-week high of $738.88 set on 30 June, while still well above the 52-week low of $202.28. It is the lowest close in the ten-session table, so no nearby support level shows in the data; the 20-session-ago close of $417.40 offers the nearest reference. The nearest resistance is the 14 October close of $446.63. Volume rose on each of the three heavy sessions, and 12,150,100 shares on 15 October, 1.84x the 50-session average, shows selling was still heavy at the latest close. The session low of $418.24 sat below the close, so the shares ended well off their lows.

6. RISK FACTORS

• Management may keep withholding a WFE view, leaving the shares dependent on peer commentary and macro data.
• Further inflation surprises that lift borrowing costs would hit chip stocks again, as on 15 October.
• Free cash flow has trailed net income, and the brief gives no explanation.
• Clean room space limits shipments next year, according to management.
• Analyst targets conflict: Evercore's $700 or $590, and consensus figures of $640.20 (MarketBeat, 39 analysts) and a $663 median (Price-target.com, six analysts) use different samples.
• Trefis's history includes drawdowns of 39.6% to 42.3% in a year.

Dated catalysts: fiscal Q4 2026 results on or around 12 November, with the site listing 12 November as the next earnings date at an EPS estimate of $4.06 and revenue estimate of $10.30bn. The brief did not find the outcome of ASML's 14 October report, which was previewed as the next sector test.

7. ACTIONABLE OUTLOOK

Short term (1-2 weeks). The shares sit at the lowest close in the table after three consecutive falls on heavy volume. Direction depends on inflation data and peer commentary, since no company event is scheduled. A recovery through $446.63 would be the first technical improvement, and a move below $418.24, the last session's low, would extend the decline.

Medium term (1-3 months). The November report is the main event. Fiscal Q4 revenue inside the $9.75B to $10.8B guided range, with the consensus estimate of $10.30bn, and any quantified outlook for equipment spending would address the concern behind the sell-off. A repeat of the August pattern, in which good guidance was met with selling, would keep pressure on the shares.

Long-term thesis. The brief shows no change in reported fundamentals: sales growth of 24.8%, higher margins and a $5B capacity investment. The 2030 targets remain untested until management adds near-term figures. This is analysis, not personal financial advice.